Erythropoietin-loaded hydrogel significantly reduces alveolar ridge resorption in human clinical trial
Background
Following tooth extraction, alveolar ridge resorption is a common and significant challenge, leading to diminished bone volume that complicates future dental implant placement. Current methods for alveolar ridge preservation often involve bone grafts or membranes, but these can have limitations regarding integration, cost, and patient morbidity. Erythropoietin (EPO), a glycoprotein hormone primarily known for stimulating red blood cell production, also exhibits pleiotropic effects, including promoting angiogenesis and tissue regeneration, making it a candidate for enhancing bone healing and preservation.
Study Design
This randomized controlled clinical trial evaluated the effect of Erythropoietin (EPO) on alveolar ridge resorption. Patients were divided into three groups: a study group receiving sockets filled with chitosan (CS)/carbon methyl cellulose (CMC)/gelatin hydrogels loaded with EPO, a positive control group receiving sockets filled with CS/CMC/gelatin hydrogels alone, and a control group undergoing natural healing. The primary endpoint was the radiographic assessment of buccal bone height at follow-up compared to baseline, evaluating bone loss.
Results
The EPO-loaded hydrogel group demonstrated superior preservation of buccal bone height. At follow-up, the average buccal bone height was 7.4±1.9 mm compared to 8.4±2.3 mm at baseline, showing a non-significant bone loss (P=0.25). In contrast, the positive control group (hydrogels alone) experienced significant bone loss, with buccal bone height averaging 7.5±3.3 mm at follow-up versus 9.4±3.8 mm at baseline (P=0.04). Similarly, the natural healing control group also showed significant bone loss, with an average buccal bone height of 7.7±3 mm at follow-up compared to 9.5±2.8 mm at baseline (P=0.04).
Key Findings
- EPO-loaded hydrogel group showed non-significant buccal bone loss (P=0.25) from 8.4±2.3 mm at baseline to 7.4±1.9 mm at follow-up.
- Positive control group (hydrogel alone) experienced significant buccal bone loss (P=0.04) from 9.4±3.8 mm to 7.5±3.3 mm.
- Natural healing control group also had significant buccal bone loss (P=0.04) from 9.5±2.8 mm to 7.7±3 mm.
- CS loaded-EPO hydrogel reduced ridge resorption compared to spontaneous healing and CS alone.
Why It Matters
This study provides compelling evidence that local delivery of EPO via a controlled-release hydrogel can effectively mitigate alveolar ridge resorption post-extraction. This finding is highly relevant for clinicians and patients seeking to preserve bone volume for future dental implant placement, potentially reducing the need for extensive bone augmentation procedures. The use of a biodegradable hydrogel for localized EPO delivery offers a promising, less invasive approach. While a specific protocol for human use isn't fully detailed, the concept of an EPO-loaded hydrogel could revolutionize standard-of-care for ridge preservation, moving towards a more biologically active and regenerative strategy.
erythropoietin
epo
alveolar-ridge-preservation
bone-regeneration
dental-implants
hydrogel